Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Root

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Cancer Discovery|June 5, 2016
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 TargetingAndrew J Aguirre, Robin M Meyers, Barbara A Weir, et al.
Nature Medicine|January 22, 2019
Small-molecule targeting of brachyury transcription factor addiction in chordomaTanaz Sharifnia, Mathias J Wawer, Ting Chen, et al.
Cell Reports|July 14, 2021
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16qJasper E Neggers, Brenton R Paolella, Adhana Asfaw, et al.
Cell Reports|August 29, 2019
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid TumorsElaine M Oberlick, Matthew G Rees, Brinton Seashore-Ludlow, et al.
Nature Genetics|October 31, 2017
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cellsRobin M Meyers, Jordan G Bryan, James M McFarland, et al.
Cell Reports|December 16, 2020
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16qJasper E Neggers, Brenton R Paolella, Adhana Asfaw, et al.
The Journal of Clinical Investigation|December 5, 2017
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Liying Chen, Gabriela Alexe, Neekesh V Dharia, et al.
Nature Communications|June 23, 2016
Integrated genetic and pharmacologic interrogation of rare cancersAndrew L Hong, Yuen-Yi Tseng, Glenn S Cowley, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Cancer Discovery|June 5, 2016
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 TargetingAndrew J Aguirre, Robin M Meyers, Barbara A Weir, et al.
Nature Medicine|January 22, 2019
Small-molecule targeting of brachyury transcription factor addiction in chordomaTanaz Sharifnia, Mathias J Wawer, Ting Chen, et al.
Cell Reports|July 14, 2021
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16qJasper E Neggers, Brenton R Paolella, Adhana Asfaw, et al.
Cell Reports|August 29, 2019
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid TumorsElaine M Oberlick, Matthew G Rees, Brinton Seashore-Ludlow, et al.
Nature Genetics|October 31, 2017
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cellsRobin M Meyers, Jordan G Bryan, James M McFarland, et al.
Cell Reports|December 16, 2020
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16qJasper E Neggers, Brenton R Paolella, Adhana Asfaw, et al.
The Journal of Clinical Investigation|December 5, 2017
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Liying Chen, Gabriela Alexe, Neekesh V Dharia, et al.
Nature Communications|June 23, 2016
Integrated genetic and pharmacologic interrogation of rare cancersAndrew L Hong, Yuen-Yi Tseng, Glenn S Cowley, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Pageof 20